Placebo to MK-1167 clinical trials

A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

This study is testing a new medicine, MK-1167, for people with mild to moderate Alzheimer's disease. Researchers want to see if it helps improve memory and thinking, and if it's safe to use. Some participants will receive the medicine, while others will get a dummy pill.